PresentationThanks, everyone, for being here. My name is Allen Gong. I'm on the medical supplies and devices team here at JPMorgan. It's my pleasure to introduce the management team at TransMedics. We're going to be starting off with some prepared remarks from CEO, Waleed Hassanein, and then we'll be joined by CFO, Gerardo, for the Q&A. So if you want to kick us off.Waleed HassaneinFounder, President, CEO & Director Great. Thanks, Al. Good afternoon, everyone. As a quick announcement, we have not released a ...

UAB “Kvartalas”, legal entity code 305475438, with its registered address at Jogailos St. 4, Vilnius, Republic of Lithuania (the Issuer), announces that, due to sufficient investor demand, the Issuer has decided to end the subscription process for the offering of the 5th tranche of bonds (ISIN LT0000411167), effective as of the time of this announcement. New subscription orders are no longer accepted. As of the time of this announcement, Nasdaq Exchange Members shall not accept any new subscription orders f ...

Luis M/iStock via Getty Images The following segment was excerpted from the Mar Vista U.S. Quality Q4 2025 Commentary. Mar Vista’s U.S. Quality strategy returned +0.20% net-of-fees in the fourth quarter of 2025. The Russell 1000® Index and the S&P 500® Index returned +2.41% and +2.65%, respectively. Stock selection within ...

Sidetrade, the Order-to-Cash AI company, announced it has obtained SOC 1® Type II and SOC 2® Type II reports with an unmodified auditor’s opinion, following audits conducted by EY France, and completed a full ISO/IEC 27001:2022 recertification. The results validate the company’s control maturity, data protection practices, and operational resilience at scale, as enterprises increasingly demand verifiable assurances on AI governance and financial process integrity, particularly in regulated environments. The ...

Core Insights - REFI Solar, part of INVL Renewable Energy Fund I, has repaid a EUR 17.5 million loan to Cordiant Capital nearly six months ahead of schedule, indicating strong financial management and operational success [1][2][4] Group 1: Loan Details and Impact - The loan from Cordiant Capital was utilized to expand solar parks in Poland and Romania, with a total capacity of 389 megawatts (MW) [2] - The early repayment of the loan enhances the fund's capital structure and attractiveness to investors, signaling a successful debt transaction [4] Group 2: Fund Performance and Strategy - INVL Renewable Energy Fund I has raised a total of EUR 97.768 million from investors through fund units and bonds issued by its controlled companies [5] - The fund focuses on early- and mid-stage renewable energy projects, including the construction and management of solar power plants in the EU and EEA [6]

Core Viewpoint - Directors of Guardian Metal Resources plc have made recent share purchases, indicating confidence in the company's future prospects [1] Summary by Relevant Categories Director Shareholdings - Oliver Friesen increased his shareholding from 1,060,557 to 1,080,657 shares by acquiring 20,100 shares at a cost of £29,748, representing 0.64% of the issued share capital post-purchase [1] - J.T. Starzecki raised his shareholding from 107,906 to 145,156 shares by purchasing 37,250 shares for £55,356, which accounts for 0.09% of the issued share capital following the transaction [1] Regulatory Compliance - The share dealings were disclosed in accordance with the EU Market Abuse Regulation, ensuring transparency in the directors' transactions [1]

Core Viewpoint - Karolinska Development AB is initiating a rights issue to raise approximately SEK 202.6 million for the continued development of existing investments and general corporate purposes [2][6]. Rights Issue Details - The rights issue involves a maximum of 675,193,985 series B shares at a subscription price of SEK 0.30 per share [6]. - The subscription period runs from January 13, 2026, to January 27, 2026, with trading in subscription rights occurring from January 13 to January 22, 2026 [4][6]. - Shareholders holding series A and B shares will have preferential rights to subscribe, with one existing share granting five subscription rights, and two subscription rights allowing the purchase of one new series B share [6]. Financial Commitments - Prior to the rights issue, the company has secured subscription undertakings from its Board of Directors and management amounting to approximately SEK 5.2 million, representing about 2.6% of the rights issue [6]. - Additionally, the company has entered into guarantee commitments totaling approximately SEK 95.2 million, which is about 47% of the rights issue, including the subscription undertakings [6]. Timeline and Trading Information - The estimated date for announcing the outcome of the rights issue is around January 29, 2026, with trading in new shares expected to commence on February 16, 2026 [4][6]. - Trading in paid subscribed shares (BTA) will occur from January 13, 2026, until around February 12, 2026 [4]. Company Overview - Karolinska Development AB is a Nordic life sciences investment company focused on identifying and developing breakthrough medical innovations [10]. - The company aims to build companies around leading scientists and management teams, co-funded by international investors, to enhance the chances of success in advancing medical innovations [11]. - The company has a portfolio of eleven companies targeting innovative treatments for serious diseases [12].

Core Insights - Valeura Energy Inc. reported a record cash position of US$305.7 million as of December 31, 2025, with no debt, aligning with its guidance outlook for 2025 [1] - The company successfully completed a drilling campaign at Block B5/27, which is expected to enhance oil production and contribute to reserves replacement [1] - The guidance outlook for 2026 aims to continue generating long-term value for shareholders [1] Q4 and Full Year 2025 Highlights - Average oil production in Q4 2025 was 24,721 barrels per day (bbls/d), leading to a full year average of 23,242 bbls/d for 2025 [1] - A total of 2.523 million barrels of oil were sold in Q4 2025, with an annual total of 8.466 million barrels sold for the full year [1] - Price realizations in Q4 2025 averaged US$64.0 per barrel, resulting in Q4 revenue of US$161.4 million and total revenue of US$594.4 million for the full year [1] - Greenhouse gas (GHG) intensity was reduced by 13% for the full year 2025, achieving a total reduction of 30% since the acquisition of the Thailand portfolio in 2023 [1] - Nine production-oriented development wells were completed at the Jasmine and Ban Yen fields in Q4 2025, achieving a 100% success rate, including a record length for a horizontal well in the Gulf of Thailand [1]

Core Viewpoint - The company announced an interim dividend of 0.60 cents per ordinary share for 2025, with equivalent amounts in Sterling and Canadian Dollars provided based on current exchange rates [1] Dividend Details - The interim dividend of 0.60 cents per ordinary share is equivalent to 0.4471 pence per share in Sterling [1] - In Canadian Dollars, the interim dividend amounts to 0.8330 Canadian cents per share [1] - The exchange rates used for conversion are US$1=£0.7452 and US$1=C$1.3884, determined on the record date of January 9, 2026 [1]

Core Insights - The presentation emphasizes two key terms: IPF (idiopathic pulmonary fibrosis) and super-prostacyclin, which are central to understanding the potential of United Therapeutics [2][3]. Group 1: Company Overview - United Therapeutics is focused on addressing the medical needs associated with IPF, a fatal condition that severely impacts patients' ability to breathe [3]. - Historically, there have only been two widely approved medicines for IPF, highlighting the limited treatment options available for this condition [3]. Group 2: Market Potential - The recent approval of a new medicine for IPF in certain jurisdictions indicates a growing interest and potential for innovation in this therapeutic area [3].